Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Late-stage clinical trials of Oralin to begin in Canada

Sep. 17, 1998

Canadian launch for minimally invasive impotence treatment

Sep. 17, 1998

RPR will introduce CombiPatch in U.S. during third quarter

Sep. 16, 1998

European-wide approval for Viagra

Sep. 16, 1998

SKB selects V-ATPase inhibitor SB-242784 for further evaluation

Sep. 16, 1998

Joint venture for development of MPS I treatment now a reality

Sep. 16, 1998

Novel glucagon receptor antagonist with potential in treating type I/type II diabetes

Sep. 15, 1998

Amgen describes preparation and use of KGF proteins

Sep. 15, 1998

Melanotan II effective as a treatment for psychogenic erectile dysfunction

Sep. 15, 1998

Development of MGDF discontinued at Amgen

Sep. 14, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...
BMS-Hengrui deal strikes panic in Washington
BioWorld
On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar...